

# PUBLIC HEALTH SERVICE

## INTER-INSTITUTIONAL AGREEMENT

### INSTITUTION-LEAD

This **Agreement** is based on the model Inter-institutional Institution Lead Agreement adopted by the U.S. Public Health Service (“**PHS**”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“**NIH**”), the Centers for Disease Control and Prevention (“**CDC**”), and the Food and Drug Administration (“**FDA**”), which are agencies of the **PHS** within the Department of Health and Human Services (“**HHS**”).

This Cover Page identifies the Parties to this **Agreement**:

The U.S. Department of Health and Human Services, as represented by

[Insert the full name of the IC]

an Institute or Center (hereinafter referred to as the “**IC**”) of the

**NIH**

and

[Insert Institution’s official name],

hereinafter referred to as the “**Institution**”,

having offices at [Insert Institution’s address],

created and operating under the laws of [Insert State].

1. BACKGROUND

- 1.1 In the course of fundamental research programs at the **IC**, under a **HHS** funding agreement (Grant/Contract No. \_\_\_\_\_), \_\_\_\_\_ (**Inventor(s)**) made or reduced to practice certain inventions which are included within the **Patent Rights**, as defined in Paragraph 2.2.
- 1.2 It is the mutual desire of the **Institution** and the **IC** that their respective undivided interests in the **Patent Rights** be administered in a manner to ensure the rapid commercialization of the **Patent Rights** and to make their benefits widely available to the public. Therefore, in accordance with [35 U.S.C. §202\(e\)](#) and [37 C.F.R. §401.10](#), the **IC** is granting an exclusive license to **IC's** rights in the **Patent Rights** to the **Institution** under the conditions set forth herein.

2. DEFINITIONS

- 2.1 “**Government**” means the government of the United States of America.
- 2.2 “**Patent Rights**” means:
- (a) Patent applications (including provisional patent applications and PCT patent applications) or patents as follows: U.S. Patent Application Serial No./U.S. Provisional Patent Application Serial No. \_\_\_\_/\_\_\_\_\_,\_\_\_\_\_, filed \_\_\_\_\_, entitled \_\_\_\_\_, and any patent application(s) claiming the benefit of priority thereof including all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of all these patents to the extent that at least one **Inventor** from the **Institution** is an **Inventor** thereon;
  - (b) to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.2(a) and to the extent that at least one **Inventor** from the **Institution** is an **Inventor**:
    - (i) continuations-in-part of 2.2(a);
    - (ii) all divisions and continuations of these continuations-in-part;
    - (iii) all patents issuing from these continuations-in-part, divisions, and continuations;
    - (iv) priority patent application(s) of 2.2(a); and
    - (v) any reissues, reexaminations, and extensions of all these patents; and
  - (c) to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.2(a) and to the extent that at least one **Inventor** from the **Institution** is an **Inventor**: all counterpart foreign and U.S. patent applications and patents to 2.2(a) and 2.2(b); and
  - (d) **Patent Rights** shall *not* include 2.2(b) or 2.2(c) to the extent that they contain one or more claims directed to new matter which is not the subject matter disclosed in 2.2(a).

- 2.3 “**Net Revenues**” means all consideration received by the **Institution** from the licensing of the **Patent Rights** pursuant to this **Agreement** less (a) **Expenses** and then (b) \_\_\_\_\_ percent (X%) of the remaining consideration for administrative overhead. In the event that a license is executed by **Institution** with a third party wherein the **Patent Rights** are licensed together with other technologies not falling under the definition of the **Patent Rights**, all consideration received by the **Institution** from the licensing of the **Patent Rights** pursuant to this **Agreement** through the third-party executed license shall correspond to the **Patent Rights’** percentage contribution to the total amount received for all licensed technologies as determined by the **Institution**.
- 2.4 “**Expenses**” means all reasonable and actual out-of-pocket costs, excluding those reimbursed by a third party, paid by the **Institution** for the preparation, filing, prosecution, and licensing of United States and foreign patent applications, extraordinary expenses as provided in Paragraph 4.6, and the maintenance of the resulting patents or patent applications, exclusive of any salaries, administrative, or other indirect costs.
- 2.5 “**Research License**” means a nontransferable, nonexclusive license to make and to use any tangible embodiment of the **Patent Rights** and to practice any process(es) included within the **Patent Rights** for purposes of internal research and not for purposes of commercial manufacture or distribution or in lieu of purchase.
- 2.6 “**Practical Application**” means to manufacture in the case of a composition or product, to practice in the case of a process or method, or to operate in the case of a machine or system; and in each case, under such conditions as to establish that the invention is being utilized and that its benefits are, to the extent permitted by law or by regulations of the **Government**, available to the public on reasonable terms.

### 3. GRANT AND RESERVATION OF RIGHTS

- 3.1 The **IC** hereby grants and the **Institution** accepts, subject to the terms and conditions of this **Agreement**, an exclusive license, including the right to sublicense, under the **Patent Rights** to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any tangible embodiment of the **Patent Rights** and to practice and have practiced any process included within the **Patent Rights**.
- 3.2 The **Government** shall have the irrevocable, royalty-free, paid-up right to practice and have practiced the **Patent Rights** throughout the world by or on behalf of the **Government** and on behalf of any foreign government or international organization pursuant to any existing or future treaty or agreement to which the **Government** is a signatory. Any license granted by the **Institution** under the terms of this **Agreement** shall be subject to this right of the **Government**.
- 3.3 The **IC** reserves the right to require the **Institution**, or its licensees, to grant sublicenses to responsible applicants, on terms that are reasonable under the circumstances when necessary to fulfill health or safety needs or when necessary to meet requirements for public use specified by Federal regulations.
- 3.4 In addition to the reserved right of Paragraph 3.3, the **IC** reserves the right to require the **Institution** to grant **Research Licenses** on reasonable terms and conditions. The purpose of these **Research Licenses** is to encourage basic research, whether conducted at an academic or corporate facility.

### 4. PATENT PROSECUTION AND PROTECTION

- 4.1 The **Institution** shall file, prosecute, and maintain patent application(s) relating to the **Patent Rights** and shall promptly provide to the **IC** all serial numbers and filing dates, together with copies of all these applications, including copies of all Patent Office actions, responses, and all other Patent Office communications. In addition, the **Institution**, shall file with Patent Offices, a Power of Attorney, that names both the **Institution** and the **IC**. This Power of Attorney shall be filed with every Patent Office involved in prosecuting all patent applications pertaining to **Patent Rights**. The **Institution** shall consult with the **IC**, when so requested, prior to communicating with any Patent Office with respect to the **Patent Rights**.

- 4.2 The **Institution** shall make an election with respect to foreign filing, upon consultation with the **IC**, including which countries foreign filing shall be done prior to the election, within eight (8) months of any United States filing. If any foreign patent applications are filed, the **Institution** shall promptly provide to the **IC** all serial numbers and filing dates. The **Institution** also shall provide the **IC** copies of foreign patent applications and Patent Office actions. The **Institution** shall consult with the **IC**, when so requested, prior to communication with any Patent Office with respect to the **Patent Rights**.
- 4.3 The **Institution** shall promptly record Assignments of domestic **Patent Rights** in the United States Patent and Trademark Office and shall promptly provide the **IC** with the original of each recorded Assignment with respect to the **IC**.
- 4.4 Notwithstanding any other provision of this **Agreement**, the **Institution** shall not abandon the prosecution of any patent application, including provisional patent applications (except for purposes of filing continuation application(s)) or the maintenance of any patent contemplated by this **Agreement**, without prior written notice to the **IC**. Upon receiving the written notice, the **IC** may, at its sole option, take over the prosecution of any patent application, or the maintenance of any patent.
- 4.5 The **Institution** shall promptly provide the **IC** with copies of all issued patents under this **Agreement**.
- 4.6 In the event that the **Institution** anticipates the possibility of any extraordinary expenditures arising from the preparation, filing, prosecution, licensing, or defense of any patent application or patent contemplated by this **Agreement**, including, without limitation, interferences, reexaminations, reissues and oppositions, the **Institution** shall provide the **IC** with all relevant information, and these extraordinary expenditures shall be included as **Expenses** only upon written agreement of the **IC**. The **Institution** and the **IC** shall agree on a mutually acceptable course of action prior to incurring these expenditures.

## 5. LICENSING

- 5.1 The **Institution** shall diligently seek licensees for the commercial development of the **Patent Rights** and shall administer the **Patent Rights** for the mutual benefit of the parties and in the public interest. The **Institution** shall ensure that any license granted for the **Patent Rights** is subject to the provisions of [37 C.F.R. Part 401](#) and the rights retained by the **Government** under this **Agreement**, including the requirement for substantial manufacture in the United States as stated in Paragraph 11.1.
- 5.2 The **Institution** shall not issue any royalty-free or paid-up licenses or assign **Patent Rights** to any third party, notwithstanding any other provision of this **Agreement**, without the prior written consent of the **IC**.
- 5.3 The **Institution** shall consult with the **IC** in the negotiation of any exclusive or partially-exclusive licenses, notwithstanding any other provision of this **Agreement**, and shall not grant these licenses without the prior review, opportunity for comment, and written approval of the **IC**.
- 5.4 Before licensing of the **Patent Rights** or any part thereof by the **Institution**, the **Institution** shall first notify and confer with the **IC** regarding any research funding related to the **Patent Rights** so as to determine the **IC**'s interest in participating in any funded collaborative research project.
- 5.5 The **Institution** shall promptly provide the **IC** with complete copies of all licenses and sublicenses granted for the **Patent Rights**.
- 5.6 **Institution** agrees that its licensees shall supply, to the Mailing Address for **Agreement** notices indicated on the Signature Page, the Office of Technology Transfer, **NIH** with inert samples of the licensed products or licensed processes, as covered by the **Patent Rights**, or their packaging for educational and display purposes only.

6. ROYALTIES AND EXPENSES

- 6.1 The **Institution** shall distribute **Net Revenues** to the **IC** concurrently with distributions it makes under the **Institution's** patent policy, but in any case not later than April 1 for the preceding calendar year, on the following basis: (a) \_\_\_\_\_ percent (X%) of the **Net Revenues** as a royalty to the **Institution** and (b) \_\_\_\_\_ percent (X%) of the **Net Revenues** as a royalty to the **IC**.
- 6.2 All payments to the **IC**, required under this **Agreement**, shall be in U.S. dollars and payment options are listed in Appendix A.
- (a) Any loss of exchange, value, taxes, or other expenses incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the **Institution**; and
- (b) Additional royalties may be assessed by the **IC** on any payment that is more than ninety (90) days overdue at the rate of one percent (1%) per month. This one percent (1%) per month rate may be applied retroactively from the original due date until the date of receipt by the **IC** of the overdue payment and additional royalties. The payment of any additional royalties shall not prevent the **IC** from exercising any other rights it may have as a consequence of the lateness of any payment.
- 6.3 The **Institution** shall submit to the **IC** annual statements of itemized **Expenses** as defined in Paragraph 2.4 and shall deduct the **Expenses** as provided for in Paragraph 2.3, except where **IC** has identified discrepancies in billing by the **Institution**, in which case, deduction of the contested item(s), as a part of the **Expenses** as provided for in Paragraph 2.4, shall be delayed pending resolution thereof.
- 6.4 In no event shall the **IC** be obligated to bear any costs for **Expenses** under this **Agreement**.
- 6.5 Each party shall be solely responsible for calculating and distributing to its respective **Inventor(s)** of the **Patent Rights** any share of **Net Revenues** in accordance with its respective patent policy, royalty policy, or Federal law during the term of this **Agreement**.

7. RECORDS AND REPORTS

- 7.1 The **Institution** shall keep complete, true, and accurate accounts of all **Expenses** and of all **Net Revenues** received by it from each licensee of the **Patent Rights** and shall permit the **IC** or the **IC's** designated agent to examine its books and records in order to verify the payments due or owed under this **Agreement**.
- 7.2 Upon request by the **IC**, the **Institution** shall submit to the **IC** an annual report, not later than April 1 of each year, setting forth the status of all patent prosecution, commercial development, and licensing activity relating to the **Patent Rights** for the preceding calendar year.

8. PATENT INFRINGEMENT

- 8.1 In the event the **IC** or the **Institution**, including its licensees, shall learn of the substantial infringement of any patent subject to this **Agreement**, the party who learns of the infringement shall promptly notify the other party in writing and shall provide the other party with all available evidence of the infringement. The **Institution** and its licensees, in cooperation with the **IC**, shall use their best efforts to eliminate the infringement without litigation. If the efforts of the parties are not successful in eliminating the infringement within ninety (90) days after the infringer has been formally notified of the infringement by the **Institution**, the **Institution** shall have the right, after consulting with the **IC**, to commence suit on its own account. The **IC** may join the **Institution's** suit or commence its own suit.
- 8.2 The **Institution** may permit its licensees to bring suit on their own account, but only if the **IC** and the **Institution** elect not to commence separately or join each other in any suit, other than as nominal party plaintiff, either by formal notice or by failure to act within the ninety (90) day period set forth in Paragraph 8.1. The **IC** shall retain the right to join any licensee's suit.

- 8.3 Neither a licensee nor the **Institution** shall take action to compel the **IC** either to initiate or to join in any suit for patent infringement. Should the **Government** be made a party to any suit by motion or any other action of a licensee or the **Institution**, the licensee or the **Institution** shall reimburse the **Government** for any costs, expenses, or fees which the **Government** incurs as a result of the motion or other action, including any and all costs incurred by the **IC** in opposing any joinder action.
- 8.4 Legal action or suits to eliminate infringement or recover damages pursuant to Paragraph 8.1 shall be at the full expense of the party by whom suit is brought. All damages recovered thereby shall first be used to reimburse each party for its expenses relating to the legal action, and the remainder of the damages shall be considered **Net Revenues**.
- 8.5 Each party agrees to cooperate with the other in litigation proceedings. The **IC** may be represented, at its expense, by counsel of its choice in any suit.

9. GOVERNING LAWS, SETTLING DISPUTES

- 9.1 This **Agreement** shall be construed in accordance with U.S. Federal law, as interpreted and applied by the U.S. Federal courts in the District of Columbia. Federal law and regulations shall preempt any conflicting or inconsistent provisions in this **Agreement**. The **Institution** agrees to be subject to the jurisdiction of U.S. courts.
- 9.2 Any controversy or any disputed claim by either party against the other arising under or related to this **Agreement** shall be submitted jointly to the **Institution's** President or designee and to the **IC** official or designee for resolution. The **Institution** and the **IC** shall be free after written decisions are issued by those officials to pursue all administrative or judicial remedies which may be available.

10. TERM AND TERMINATION

- 10.1 This **Agreement** is effective when signed by all parties, unless the provisions of Paragraph 11.9 are not fulfilled, and shall extend to the expiration of the last to expire of the patents included within the **Patent Rights** unless otherwise terminated by operation of law or by acts of the parties in accordance with the terms of this **Agreement**.
- 10.2 The **Institution** may terminate this **Agreement** upon at least sixty (60) days written notice to the **IC**, but in any event not less than sixty (60) days prior to the date on which any pending Patent Office actions need be taken to preserve patent rights for the benefit of the parties hereto.
- 10.3 In the event the **Institution** has made no commitments to any third party for exclusive license rights relating to the **Patent Rights**, the **IC** may terminate this **Agreement** for any reason upon thirty (30) days written notice to the **Institution**. During the term of any option agreement or license agreement to any third party for exclusive license rights relating to the **Patent Rights** between the **Institution** and an optionee or licensee, the **IC** may terminate this **Agreement** when:
- (a) it is determined by the **IC's**:
- (i) The **Institution** or its licensee has not taken and is not expected to take effective steps to achieve **Practical Application** of the **Patent Rights**;
  - (ii) Termination is necessary to alleviate health or safety needs which are not reasonably satisfied by the **Institution** or its licensee;
  - (iii) Termination is necessary to meet requirements for public use specified by Federal law or regulations and these requirements are not reasonably satisfied by the **Institution** or its licensees; or

- (iv) Termination is necessary because the requirements of 35 U.S.C. §204 have not been satisfied or waived or because a licensee of the exclusive right to use or sell the **Patent Rights** in the United States is in breach of its agreement obtained pursuant to Section 204;
  - (b) the **Institution** or affected third party has been notified of this determination and has been given at least thirty (30) days to provide a response to this determination, and
  - (c) the **Institution's** or affected third party's response to the determination of 10.3(a)(i)-(iv) is determined to be unsatisfactory by the Office of Technology Transfer.
- 10.4 The **IC** may terminate this **Agreement** in whole or in part if:
- (a) the **Institution** fails to make any payment or periodic reports required by this **Agreement**;
  - (b) the **Institution** has willfully made a false statement of, or willfully omitted, a material fact in the negotiation of the **Agreement** or in any report required by the **Agreement**;
  - (c) the **Institution** has committed a substantial breach of a covenant or duty contained in this **Agreement**; or
  - (d) the **IC** and the **Institution** are involved in a dispute under this **Agreement** which cannot be resolved under the procedures specified in Paragraph 9.2. If the **Agreement** is terminated under this Paragraph 10.4, the **IC** agrees to provide affected licensees an opportunity to license the **Patent Rights** subject to the restrictions of [37 C.F.R. Part 404](#), under terms as may have been agreed to by the **Institution**.

## 11. GENERAL

- 11.1 The **Institution** agrees that, for use and sale of the **Patent Rights** in the United States, any products embodying the **Patent Rights**, or produced through use of the **Patent Rights**, shall be manufactured substantially in the United States unless a waiver is granted by the **IC**.
- 11.2 All **Agreement** notices required or permitted by this **Agreement** shall be given by prepaid, first class, registered or certified mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed to the other party at the address designated on the following Signature Page, or to the other address as may be designated in writing by such other party. **Agreement** notices shall be considered timely if the notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.
- 11.3 This **Agreement** shall not be construed to confer on any person any immunity from or defenses under the antitrust laws or from a charge of patent misuse, and the acquisition and use of rights pursuant to this **Agreement** shall not be immunized from the operation of state or Federal law by reason of the source of the grant.
- 11.4 It is agreed that no waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent or similar breach or default.

- 11.5 This **Agreement** is binding upon and shall inure to the benefit of the parties hereto and their successors or assigns, but this **Agreement** may not be assigned by either party without the prior written consent of the other party.
- 11.6 This **Agreement** confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of the **IC** other than the **Patent Rights** regardless of whether such patents are dominant or subordinate to the **Patent Rights**.
- 11.7 Any modification to this **Agreement** must be in writing and agreed to by both parties.
- 11.8 It is understood and agreed by the **Institution** and the **IC** that this **Agreement** constitutes the entire agreement between the parties, and that all prior agreements respecting the subject matter hereof, either written or oral, expressed or implied, shall be abrogated, canceled, and are null and void and of no effect.
- 11.9 The terms and conditions of this **Agreement** shall, at the **IC's** sole option, be considered by the **IC** to be withdrawn from **Institution's** consideration and the terms and conditions of this **Agreement**, and the **Agreement** itself to be null and void, unless this **Agreement** is executed by the **Institution** and a fully executed original is received by the **IC** within sixty (60) days from the date of the **IC's** signature found at the Signature Page.

**SIGNATURES BEGIN ON NEXT PAGE**



## NIH INTERINSTITUTIONAL AGREEMENT – INSTITUTION

### SIGNATURE PAGE

IN WITNESS WHEREOF, the parties hereto have executed this **Agreement** in duplicate originals by their respective duly authorized officers, who have affixed their signatures hereunto, on the day and year hereinafter written. Any communication or notice to be given shall be forwarded to the respective addresses listed below.

For the **IC**:

\_\_\_\_\_  
Name  
Title  
Office  
National Institutes of Health

\_\_\_\_\_  
Date

Mailing Address or E-mail Address for **Agreement** notices and reports:

E-mail: [LicenseNotices\\_Reports@mail.nih.gov](mailto:LicenseNotices_Reports@mail.nih.gov) (preferred)

Mail: License Compliance and Administration  
Monitoring & Enforcement  
Office of Technology Transfer  
National Institutes of Health  
6700B Rockledge Drive, Suite 2500, MS 6911  
Bethesda, Maryland 20892-6911 U.S.A.

(For courier deliveries please check <https://www.ott.nih.gov/licensing/license-noticesreports>)

For the **Institution**:

Upon information and belief, the undersigned expressly certifies or affirms that the contents of any statements of the **Institution** made or referred to in this **Agreement** are truthful and accurate.

\_\_\_\_\_  
Signature of Authorized Official

\_\_\_\_\_  
Date

\_\_\_\_\_  
Printed Name

\_\_\_\_\_  
Title

Official and Mailing Address for **Agreement** notices:

\_\_\_\_\_  
Name

\_\_\_\_\_  
Title

Mailing Address:

---

---

---

---

Email Address: \_\_\_\_\_

Phone: \_\_\_\_\_

Fax: \_\_\_\_\_

Official and Mailing Address for Financial notices (The **Institution's** contact person for royalty payments)

\_\_\_\_\_  
Name

\_\_\_\_\_  
Title

Mailing Address:

---

---

---

---

Email Address: \_\_\_\_\_

Phone: \_\_\_\_\_

Fax: \_\_\_\_\_

Any false or misleading statements made, presented, or submitted to the **Government**, including any relevant omissions, under this **Agreement** and during the course of negotiation of this **Agreement** are subject to all applicable civil and criminal statutes including Federal statutes [31 U.S.C. §§3801-3812](#) (civil liability) and [18 U.S.C. §1001](#) (criminal liability including fine(s) or imprisonment).

## **APPENDIX A – ROYALTY PAYMENT OPTIONS**

**Checks are no longer accepted.**

New Payment Options Effective September 2024

**The License Number (L-xxx-xxxx-x) MUST appear on payments, reports, and correspondence.**

**Agency Contacts:** Office of Technology Transfer (OTT) [OTT-Royalties@mail.nih.gov](mailto:OTT-Royalties@mail.nih.gov)

**Credit and Debit Card Payments:** Credit and debit card payments can be submitted for amounts up to \$24,999. Submit your payment through the U.S. Treasury web site located at:  
<https://www.pay.gov/public/form/start/28680443>.

**Electronic Funds Wire Transfers:** The following account information is provided for wire payments. In order to process payment via Electronic Funds Wire Transfer sender MUST supply the following information within the transmission:

Drawn on a **U.S. bank account** via FEDWIRE:

Please provide the following instructions to your Financial Institution for the remittance of Fedwire payments to the **NIH ROYALTY FUND**.

<b>Fedwire Field Tag</b>	<b>Fedwire Field Name</b>	<b>Required Information</b>
{ 1510 }	Type/Subtype	<b>1000</b>
{ 2000 }	Amount	<i>(enter payment amount)</i>
{ 3400 }	Receiver ABA routing number*	<b>021030004</b>
{ 3400 }	Receiver ABA short name	<b>TREAS NYC</b>
{ 3600 }	Business Function Code	<b>CTR (or CTP)</b>
{ 4200 }	Beneficiary Identifier (account number)	<i>(enter 12-digit gateway account #)</i> <b>875080031006</b>
{ 4200 }	Beneficiary Name	<i>(enter agency name associated with the Beneficiary Identifier)</i> <b>DHHS / NIH (75080031)</b>
{ 5000 }	Originator	<i>(enter the name of the originator of the payment)</i> <b>COMPANY NAME</b>
{ 6000 }	Originator to Beneficiary Information - Line 1	<i>(enter information to identify the purpose of the payment)</i> <b>ROYALTY</b>
{ 6000 }	Originator to Beneficiary Information - Line 2	<i>(enter information to identify the purpose of the payment)</i> <b>LICENSE NUMBER (L-xxx-xxxx-x)</b>
{ 6000 }	Originator to Beneficiary Information - Line 3	<i>(enter information to identify the purpose of the payment)</i> <b>INVOICE NUMBER</b>
{ 6000 }	Originator to Beneficiary Information - Line 4	<i>(enter information to identify the purpose of the payment)</i>
Notes: *The financial institution address for Treasury's routing number is 33 Liberty Street, New York, NY 10045. **Anything other than the 12-digit gateway account # will cause the Fedwire to be returned.		

Drawn on a **non-US bank account** via FEDWIRE:

The following instructions pertain to the Fedwire Network. Deposits made in US Dollars (USD).

Should your remitter utilize a correspondent US domestic bank in transferring electronic funds, the following Fedwire instructions are applicable.

<b>Fedwire Field Tag</b>	<b>Fedwire Field Name</b>	<b>Required Information</b>
{1510}{1510}	Type/Subtype	<b>1000</b>
{2000}	Amount	<i>(enter payment amount)</i>
{3100}	Sender Bank ABA routing number	<i>(enter the US correspondent bank's ABA routing number)</i>
{3400}	Receiver ABA routing number*	<b>021030004</b>
{3400}	Receiver ABA short name	<b>TREAS NYC</b>
{3600}	Business Function Code	<b>CTR (or CTP)</b>
{4200}	Beneficiary Identifier (account number)**	<i>(enter 12-digit gateway account #)</i> <b>875080031006</b>
{4200}	Beneficiary Name	<i>(enter agency name associated with the Beneficiary Identifier)</i> <b>DHHS / NIH (75080031)</b>
{5000}	Originator	<i>(enter the name of the originator of the payment)</i> <b>COMPANY'S NAME</b>
{6000}	Originator to Beneficiary Information - Line 1	<i>(enter information to identify the purpose of the payment)</i> <b>ROYALTY</b>
{6000}	Originator to Beneficiary Information - Line 2	<i>(enter information to identify the purpose of the payment)</i> <b>LICENSE NUMBER (L-xxx-xxxx-x)</b>
{6000}	Originator to Beneficiary Information - Line 3	<i>(enter information to identify the purpose of the payment)</i> <b>INVOICE NUMBER</b>
{6000}	Originator to Beneficiary Information - Line 4	<i>(enter information to identify the purpose of the payment)</i>
Notes: *The financial institution address for Treasury's routing number is 33 Liberty Street, New York, NY 10045. **Anything other than the 12-digit gateway account # will cause the Fedwire to be returned.  <b>SWIFT CODE: FRNYUS33</b>		

### Automated Clearing House (ACH)

The IC encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). ACH payments can be submitted by two methods: Pay.gov (for US banks only) or standard ACH payment (US and non-US banks accepted).

**Pay.gov:** ACH payments can be submitted for US banks only. Submit your ACH payment through the U.S Treasury web site located at: <https://www.pay.gov/public/form/start/28680443>.

**Standard ACH:** credits can be submitted for payments up to \$99,999,999 for US and International banks. Please provide the following instructions to your Financial Institution for the remittance of Automated Clearing House (ACH) credits to the United States Department of Health of Human Services - National Institutes of Health (NIH):

Drawn on a **US** or **non-US bank account** via standard ACH:

NACHA Record Type Code	NACHA Field	NACHA Data Element Name	Required Information
5	3	Company Name	(enter the name of the payor)
5	6	Standard Entry Class Code	<b>CTX</b>
5	9	Effective Entry Date	(enter intended settlement date)
6	2	Transaction Code*	<b>22</b>
6	3 & 4	Receiving DFI Identification (ABA routing #)	<b>051036706</b>
6	5	DFI Account Number	<b>875080031006</b>
6	6	Amount	(enter payment amount)
6	8	Receiving Company Name	(enter the identifying information)
7	3	Payment Related Information	(see format instructions below)

Additional Payment Related Information should be included in NACHA Record 7 Field 3 and must conform to the ANSI ASC X12 standards using the EDI 820 Transaction Set Data Segments. A sample format follows.

Segment Contents	Element Descriptions
RMR*AR*License number**Amount being paid\N1*8R*Licensee Name\**RMR*AR*license number 2**Amount being Paid 2\N1*8R*Licensee Name2\**	DATA SEGMENT - Remittance Advice Accounts Receivable <b>RMR</b> * (delimiter) Reference Identification Qualifier: <b>AR</b> Accounts Receivable Number * (delimiter) <b>License number</b> (L-xxx-xxxx-x) * (delimiter) * (delimiter) Monetary Amount: Amount being paid \ (segment terminator) DATA SEGMENT – Name: <b>N1</b> * (delimiter) Entity Identifier Code: <b>8R</b> Identifies customer * (delimiter) Name: <b>Licensee name</b> \ (segment terminator)
Example: Licensee LLC with Licensee number L-xxx-20xx-x pays \$1,000.00 <b>RMR*AR*L-xxx-20xx-x**1000.00\N1*8R*Licensee LLC \</b>	

**ACH debits are not permitted to this ABA routing number. All debits received will be automatically rejected/returned.**

Agency Contacts: Office of Technology Transfer (OTT) [OTT-Royalties@mail.nih.gov](mailto:OTT-Royalties@mail.nih.gov)